Registry Study of the Working Group on Cervical Pathology and Colposcopy (AGCPC) on the Diagnostic Algorithm for the New Cervical Cancer Screening – Initial Data

Abstract

Introduction

For the first time since 1971, new regulations were introduced for cervical cancer screening as an organized cancer screening guideline (oKFE-RL) starting 1 January 2020. From the age of 20, a cytological smear test is performed annually, and from the age of 35, so-called co-testing (cytology and test for high-risk HPVs) is performed every three years. In case of abnormalities, the algorithm is used as the basis for investigation. According to this diagnostic algorithm, even so-called low-risk groups receive early colposcopic evaluation. This approach has been heavily debated and serves as the basis for this registry study.

Methods

All patients who presented to the centers for a colposcopy as part of the diagnostic algorithm were included after signing an informed consent form. The following findings were obtained: Medical history, colposcopy, histology, and cytology findings, as well as possible therapies and their findings. The aim was to evaluate the frequency of the target lesions cervical intraepithelial neoplasia (CIN) 2+/CIN 3+ in the respective groups.

Result

A total of 4763 patients were enrolled in the study from July 2020 to October 2022. As a referral diagnosis, HPV persistence (HPV: human papillomavirus) with group I was determined in 23.9% (1139), HPV persistence with group II-a in 2.1% (100), II-p (ASC-US) in 11.2% (535), and II-g (AGC endocervical NOS) in 1.3% (64). III-p (ASC-H) and III-g (AGC endocervical favor neoplastic) were found in 9.4% (447) and 2.2% (107), respectively, IIID1 (LSIL) in 19% (906), IIID2 (HSIL, moderate dysplasia) in 18.9% (898), IVa-p (HSIL, severe dysplasia) in 10.7% (508), IVa-g (AIS) in 0.7% (31), IVb-p (HSIL with features suspicious for invasion) and IVb-g (AIS with features suspicious for invasion) in 0.3% (15), 0.1% (6), and 7 with suspected invasion V-p (squamous cell carcinoma)/V-g (endocervical adenocarcinoma) (0.1%). In the IVa-p group (HSIL, severe dysplasia), 67.7% had CIN 2+ and 56.5% had CIN 3+, adenocarcinoma in situ (AIS), and adenocarcinoma. If the histology of the excised tissue specifically based on the colposcope findings was also evaluated, CIN 2+ was found in 79.7% of cases, and CIN 3+ in 67.3% of cases. In IIID2 (HSIL, moderate dysplasia), CIN 2+ was detected in 50.9%, and CIN 3+/AIS in 28.3%. After evaluating patients who underwent surgery immediately, this increased to 53.0% for CIN 2+ and 29.3% for CIN 3+/AIS. In IIID1 (LSIL), CIN 2+ was detected in 27.4% and CIN 3+/AIS in 11.7%, and in II-p (ASC-US), CIN 2+ was detected in 23.4% and CIN 3+ and AIS in 10.8%, and in II-g (AGC endocervical NOS), CIN 2+ was detected in 34.4% and CIN 3+ in 23.4%. In the HPV persistence/II-a and I group, 21% showed CIN 2+, and 12.1% showed CIN 3+ and AIS, and 13% showed CIN 2+ and 5.9% showed CIN 3+ and AIS. In patients who were HPV-negative and had further diagnostics performed on the basis of cytologic smear alone, 27.9% had CIN 2+, and 14.1% had CIN 3 and AIS.

Discussion

In a synopsis of the present findings of our initial data of the registry study on the new cervical cancer screening, according to the organized early cancer screening guideline (oKFE-RL), we could show that the target lesion CIN 3+ and AIS is detected unexpectedly frequently in a not insignificant proportion, especially in the cytological low-risk group. Currently, we cannot answer whether this can reduce the incidence and mortality of cervical carcinoma, but this could be an initial indication of this and will be reviewed in further long-term evaluations.

Keywords

cervical cancer screening - cancer screening guideline (oKFE-RL) - co-test - diagnostic algorithm - cervical intraepithelial neoplasia - human papillomavirus (HPV)

Publikationsverlauf

Eingereicht: 11. Juli 2023

Angenommen nach Revision: 19. August 2023

Artikel online veröffentlicht:
05. Oktober 2023

• References/Literatur

• 1 Gemeinsamer Bundesausschuss. Beschluss des Gemeinsamen Bundesausschusses über eine Änderung der Krebs-früherkennungs-Richtlinie und eine Änderung der Richtlinie für organisierte Krebsfrüherkennungsprogramme: Programm zur Früherkennung von Zervixkarzinomen. gyn 2019; 22 (Suppl. 1) 6-24
• 2 Gemeinsamer Bundesausschuss. Tragende Gründe zum Beschluss des Gemeinsamen Bundesausschusses über eine Änderung der Krebsfrüherkennungs-Richtlinie und eine Änderung der Richtlinie für organisierte Krebsfrüherkennungsprogramme: Programm zur Früherkennung von Zervixkarzinomen. gyn 2019; 22 (Suppl. 1) 25-46
• 3 Griesser H, Marquardt K, Jordan B. et al. Gynäkologische Zytodiagnostik der Zervix: Münchner Nomenklatur III. Frauenarzt 2013; 54: 1042-1048
• 4 Marquardt K, Kossowski I, Pfandzelter R. Münchner Nomenklatur III. Bundesweite Jahresstatistik nach der Nomenklaturreform. Frauenarzt 2017; 58: 706-712
• 5 Marquardt K, Ziemke P. Münchner Nomenklatur III: Klassifikation nach Risikoverlaufsbeobachtung bei auffälligen plattenepithelialen Befunden. Pathologe 2018; 39: 57-64
• 6 Katki HA, Schiffman M, Castle PE. et al. Five-year risks of CIN 3+ and cervical cancer among women with HPV testing of ASC-US Pap results. J Lower Gen Tract Dis 2013; 17: 36-42
• 7 Katki HA, Schiffman M, Castle PE. Five-Year Risks of CIN 2+ and CIN 3+ among women with HPV-positive and HPV-negative LSIL Pap results. J Lower Gen Tract Dis 2013; 17: 43-49
• 8 Gemeinsamer Bundesausschuss. Screening auf Gebärmutterhalskrebs soll wie geplant starten – Dokumentationsvorgaben werden befristet ausgesetzt. Zugriff am 03. Juli 2023 unter: https://www.g-ba.de/presse/pressemitteilungen/829
• 9 Bornstein J, Bentley J, Bösze P. et al. 2011 colposcopic terminology of the International Federation for Cervical Pathology and Colposcopy. Obstet Gynecol 2012; 120: 166-172
• 10 Marquardt K, Büttner HH, Broschewitz U. et al. Persistent carcinoma in cervical cancer screening: non-participation is the most significant cause. Acta Cytol 2011; 55: 433-437
• 11 Xhaja A, Ahr A, Zeiser I. et al. Two Years of Cytology and HPV Co-Testing in Germany: Initial Experience. Geburtshilfe Frauenheilkd 2022; 82: 1378-1386
• 12 Marquardt K, Ziemke P. Co-Test im Zervixkarzinom-Screening: Die erste Runde. Gynäkologie 2022; 55: 867-874
• 13 Bekos C, Schwameis R, Heinze G. et al. Influence of age on histologic outcome of cervical intraepithelial neoplasia during observational management: results from large cohort, systematic review, meta-analysis. Sci Rep 2018; 8: 6383
• 14 Ostör AG. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol 1993; 12: 186-192
• 15 Tainio K, Athanasiou A, Tikkinen KAO. et al. Clinical course of untreated cervical intraepithelial neoplasia grade 2 under active surveillance: systematic review and meta-analysis. BMJ 2018; 360: k499
• 16 Moore K, Cofer A, Elliot L. et al. Adolescent cervical dysplasia: histologic evaluation, treatment, and outcomes. Am J Obstet Gynecol 2007; 197: 141.e1-141.e6
• 17 Melnikow J, Nuovo J, Willan AR. et al. Natural history of cervical squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol 1998; 92: 727-735
• 18 McCredie MRE, Sharples KJ, Paul C. et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol 2008; 9: 425-434
• 19 Statistisches Bundesamt (www.destatis.de). Rauchgewohnheiten nach Altersgruppen und Geschlecht. Zugriff am 03. Juli 2023 unter: https://www.destatis.de/DE/Themen/Gesellschaft-Umwelt/Gesundheit/Gesundheitszustand-Relevantes-Verhalten/Tabellen/liste-rauchverhalten.html
• 20 Berger L, Wolf-Breitinger M, Weiß C. et al. Prevalence of higher-grade dysplasia in persistently high-risk human papillomavirus positive, cytology negative women after introduction of the new cervical cancer screening in Germany. Cancer Causes Control 2023; 34: 469-477
• 21 Jastania R, Geddie WR, Chapman W. et al. Characteristics of apparently false-negative digene hybrid capture 2 high-risk HPV DNA testing. Am J Clin Pathol 2006; 125: 223-228
• 22 Reich O, Regauer S, Kashofer K. Possibly carcinogenic HPV subtypes are a cause of HSIL and negative clinical HPV tests – A European prospective single center study. Gynecol Oncol 2020; 158: 112-116
• 23 Freudenreich R, Weiss M, Engler T. et al. Characterization and clinical management of abnormal cytology findings in pregnant women: a retrospective analysis. Arch Gynecol Obstet 2022; 306: 2017-2026
• 24 Ehret A, Bark VN, Mondal A. et al. Regression rate of high-grade cervical intraepithelial lesions in women younger than 25 years. Arch Gynecol Obstet 2023; 307: 981-990
• 25 Kyrgiou M, Koliopoulos G, Martin-Hirsch P. et al. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet 2006; 367: 489-498
• 26 Stubert J, Stratmann E, Gerber B. et al. Risk factors of preterm birth in women after local treatment of cervical intraepithelial neoplasia – a retrospective cohort study. Geburtshilfe Frauenheilkd 2022; 82: 1397-1405